All PRODUCTS

  1. PRODUCTS
Raoh-Fang Pwu publications

Raoh-Fang Pwu publications

23896851000.jpg
/
DETAIL
期刊論文Journal articles
  1. 楊雯雯、吳慧敏、劉嘉玲、鄭國本、余明隆、蒲若芳、盧勝男、簡榮南（2023）。C型肝炎病毒抗體快篩試劑的運用。台灣公共衛生雜誌，42(6)，594-611。
  2. Wen-Wen Yang, Yi-Chen Juan, Grace Hui-Min Wu, Raoh-Fang Pwu. The Critical Intersect of Regulations, Health Technology Assessment, and Drug Safety Assessments. Drug Saf (2023). https://doi.org/10.1007/s40264-023-01386-1
  3. Rong-Nan Chien, Sheng-Nan Lu, Grace Hui-Min Wu, Wen-Wen Yang, Raoh-Fang Pwu, Chia-Ling Liu, Kuo-Pen Cheng, Shih-Chung Chen, Chien-Jen Chen, Policy and Strategy for Hepatitis C Virus Elimination at the National Level: Experience in Taiwan, The Journal of Infectious Diseases, Volume 228, Issue Supplement_3, 15 September 2023, Pages S180–S188, https://doi.org/10.1093/infdis/jiad016
  4. Chien-Chin Chen, Chyong-Huey Lai, Chih-Long Chang, Wen-Fang Cheng, Raoh-Fang Pwu, Jane Tsai, Peng-Hui Wang, Jacqueline Whang-Peng, Gi-Ming Lai, Managing the transition in cervical screening methods for Taiwan: Policy recommendations and perspectives, Journal of the Formosan Medical Association, 2023, (in press) https://doi.org/10.1016/j.jfma.2023.06.018.
  5. 楊雯雯、劉嘉玲、吳慧敏、鄭國本、盧勝男、簡榮南、蒲若芳. 推動消除C肝政策之回顧. 台灣衛誌；2023:42(2):165-179.
  6. KC S, Lin LW, Bayani DBS, Zemlyanska Y, Adler A, Ahn J, Chan K, Choiphel D, Genuino-Marfori AJ, Kearney B, Liu Y, Nakamura R, Pearce F, Prinja S, Pwu RF, Shafie AA, Sui B, Suwantika A, Tunis S, Wu H, Zalcberg J, Zhao K, Isaranuwatchai W, Teerawattananon Y, & Wee H. (2023). What, Where, and How to Collect Real-World Data and Generate Real-World Evidence to Support Drug Reimbursement Decision-Making in Asia: A reflection into the Past and A Way Forward. International Journal of Health Policy and Management, 12(1), 1-9. doi: 10.34172/ijhpm.2023.6858
  7. Shiroiwa T, Murata T, Ahn J, Li X, Nakamura R, Teerawattananon Y, Kun Z, Shafie AA, Valverde H, Lam H, Ng K, Nadjib M, Pwu RF, Nugraha RR, Chen YC & Fukuda T. (2022). Developing a New Region-Specific Preference-Based Measure in East and Southeast Asia. Value in health regional issues, 32, 62–69. https://doi.org/10.1016/j.vhri.2022.07.002
  8. 楊雯雯、吳慧敏、盧勝男、劉嘉玲、鄭國本、蒲若芳. 滾動調整2025年C肝消除治療目標數. 台灣衛誌；2022:41(6):567-71.
  9. Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, Caulley L, Chaiyakunapruk N, Greenberg D, Loder E, Mauskopf J, Mullins CD, Petrou S, Pwu RF, Staniszewska S. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. Value Health. 2022; 25: 3-9.
  10. Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, Caulley L, Chaiyakunapruk N, Greenberg D, Loder E, Mauskopf J, Mullins CD, Petrou S, Pwu RF, Staniszewska S. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force. Value Health. 2022; 25: 10-31.
  11. Lu CY, Tang CH, Fu T, Pwu RF, Ho YF. Pneumococcal conjugate vaccines in Taiwan: Optimizing health gains in children and older adults through constrained optimization modeling: Pneumococcal conjugate vaccines optimization in Taiwan. Int J Infect Dis. 2021. Nov 5;S1201-9712(21)00851-1.  doi: 10.1016/j.ijid.2021.10.058. Online ahead of print.
  12. Chien RN, Lu SN, Pwu RF, Wu GH, Yang WW, Liu CL. Taiwan accelerates its efforts to eliminate hepatitis C. Glob Health Med. Released July 05, 2021. Online ISSN 2434-9194. Doi:https://doi.org/10.35772/ghm.2021.01064.
  13. Wu GHM, Yang WW, Liu CL, Pwu RF, Chien RN, Lee PC, Chen SC, Chen DS, Lu SN. The epidemiological profile of chronic hepatitis C with advanced hepatic fibrosis regarding virus genotype in Taiwan: A nationwide study. J Formos Med Assoc. 2021; 120: 1444-51.
  14. Lou J, KC S, Toh K, Dabak S, Adler A, Ahn J, Bayani D, Chan K, Choiphel D, Chua B, Genuino AJ, Guerrero AM, Kearney B, Lin LW, Liu Y, Nakamura R, Pearce F, Prinja S, Pwu RF, Shafie AA, Sui B, Suwantika A, Teerawattananon Y, Tunis S, Wu HM, Zalberg J, Zhao K, Isaranuwatchai W, Wee HL. Real-world data for health technology assessment for reimbursement decisions in Asia: Current landscape and a way forward. International Journal of Technology Assessment in Health Care. 2020, 1-7. doi:10.1017/S0266462320000628
  15. Sarin SK, Kumar M, Eslam M, George J, Al Mahtab M, Akbar SMF, Jia J, Tian Q, Aggarwal R, Muljono DH, Omata M, Ooka Y, Han KH, Lee HW, Jafri W, Butt AS, Chong CH, Lim SG, Pwu RF, Chen DS. (2020). Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission. The lancet. Gastroenterology & hepatology, 5(2), 167–228. https://doi.org/10.1016/S2468-1253(19)30342-5
  16. 劉嘉玲、楊雯雯、吳慧敏、鄭國本、蒲若芳.  臺灣 C 型肝炎消除的國家政策與軌跡. 愛之關懷. 2019;109:6-16.
  17. Teerawattananon Y, Rattanavipapong W, Lin L, Dabak S, Gibbons B, Isaranuwatchai W, Toh K, Cher B, Pierce F, Bayani D, Nakamura R, Pwu R, Shafie A, Adhikari D, Prinja S, Babidge, W. Landscape analysis of health technology assessment (HTA): Systems and practices in Asia. International Journal of Technology Assessment in Health Care, 2019;35(6):416-421. doi:10.1017/S0266462319000667
  18. 從英國發展早期感知與預警系統的經驗為例，看台灣健康照護體系之應用. 楊雯雯、蒲若芳. 台灣衛誌 2019；38(3)：236-251. 
  19. Teerawattananon Y, Luz K, Yothasmutra C, Pwu RF, Ahn J, Shafie AA, Chalkidou K, Tantivess S, Santatiwongchai B, Rattanavipapong W, Dabak S. HISTORICAL DEVELOPMENT OF THE HTAsiaLINK NETWORK AND ITS KEY DETERMINANTS OF SUCCESS. International Journal of Technology Assessment in Health Care, 2018;34(3), 260-266. doi:10.1017/S0266462318000223
  20. Shantakumar S, Pwu RF, D’Silva L, Wurst K, Kuo YW, Yang YY, Juan YC, Chan KA. Burden of asthma and COPD overlap (ACO) in Taiwan: a nationwide population-based study. BMC Pulm Med. 2018;18(1):16
  21. Wu GH, Pwu RF, Chen SC. Achieving hepatitis C elimination in Taiwan-Overcoming barriers by setting feasible strategies. J Formos Med Assoc, 117 (2018), pp. 1044-1045
  22. Hailey D, Werko S, Rosen M, Macpherson K, Myles S, Gallegos Rivero V, Hipolito-Olivares C, Sihvo S, Pwu RF, Yang WW, Chen YC, Perez Galan A, Aleman A, Villamil E. Influence of Health Technology Assessment and Its Measurement. Int J Technol Assess Health Care 2016;32(6): 376-384.
  23. Chiu WT, Pwu RF, Gau CS. Affordable health technology assessment in Taiwan: A model for middle-income countries. J Formos Med Assoc. 2015;114(6):481-3.
  24. Soon SS, Lopes G, Lim HY, Wong-Rieger D, Bahri S, Hickinbotham L, Jha A, Ko BS, MacDonell D, Pwu RF, Shih R, Sirachainan E, Suh DC, Wale J, Zhang X, Wee HL. A call for action to improve access to care and treatment for patients with rare diseases in the Asia-Pacific region. Orphanet J Rare Dis. 2014; 9: 137.
  25. Tan EC, Pwu RF, Chen DR, Yang MC. Is a diabetes pay-for-performance program cost-effective under the National Health Insurance in Taiwan? Qual Life Res. 2014;23(2):687-96.
  26. Hailey D, Werko S, Bakri R, Cameron A, Gohlen B, Myles S, Pwu RF, Yothasamut J. Involvement of consumers in health technology assessment activities by Inahta agencies. Int J Technol Assess Health Care. 2013;29(1): 79-83.
  27. Aljunid SM, Srithamrongsawat S, Chen W, Bae SJ, Pwu RF, Ikeda S, et al. Health-Care Data Collecting, Sharing, and Using in Thailand, China Mainland, South Korea, Taiwan, Japan, and Malaysia. Value in health. 2012;15(1):S132-S8.
  28. Chow IH, Tang CH, You SL, Liao CH, Chu TY, Chen CJ, Chen CA, Pwu RF. Cost-effectiveness analysis of human papillomavirus DNA testing and Pap smear for cervical cancer screening in a publicly financed health-care system. Br J Cancer 2010;103:1773-82.
  29. Pwu RF, Liu CY, Ko SY, Tsai IC, Yang YK. Pharmacoeconomic evaluation of paliperidone extended release versus olanzapine or quetiapine in the treatment for patients with schizophrenia in Taiwan. Taiwanese Journal of Psychiatry [Taipei] 2010; 24: 281-91.
  30. Liao CH, Liu JT, Pwu RF, You SL, Chow I, Tang CH. Valuation of the economic benefits of human papilomavirus vaccine in Taiwan. Value in Health, 2009, 12(S3), S74-77.
  31. Tang CH, Pwu RF, Tsai IC, Wang HI, You SL, Chen CA, Scuffham PA, Hsieh CY, Chou CY, Lin SR, Chen YD, Chen CJ. Costs of cervical cancer and precancerous lesions treatment in a publicly financed health care system. Arch Gynecol Obstet 2009.
  32. Dasbach EJ, Insinga RP, Yang YC, Pwu RF, Lac C, Elbasha, EH. The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan. Asian Pacific J Cancer Prev 2008; 9 (3): 459-566.
  33. Lacey L, Chien RN, Chuang WL, Pwu RF. Economic evaluation of chronic hepatitis B treatments in Taiwan. J Gastroenterol Hepatol. Apr 2008;23(4):571-579.
  34. Lin MS, Dai YS, Pwu RF, Chen YH, Chang NC. Risk estimates for drugs suspected of being associated with Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control study. Internal Medicine Journal 2005; 35 (3):188-190.
  35. Wang SJ, Fuh JL, Juang KD, Lu SR, Hsu LC, Chen WT, Pwu RF. Evolution of migraine diagnosis in adolescents: a 3-year annual survey. Cephalalgia 2005; 25(5):333-8.
  36. Hsu HC, Pwu RF. Too Late to Quit? Effect of Smoking and Smoking Cessation on Morbidity and Mortality Among the Elderly in a Longitudinal Study. The Kaohsiung Journal of Medical Sciences 2004; 20(10):484-91.
  37. Fuh JL, Pwu RF, Wang SJ, Chen YH. Measuring Alzheimer’s Disease Progression with Transition Probabilities in the Taiwanese Population. International journal of geriatric psychiatry 2004; 19(3):266-70.
  38. Pwu RF, Chan KA.  Cost-effectiveness analysis of interferon-alpha therapy in the treatment of chronic hepatitis B in Taiwan.  J Formos Med Assoc 2002;101:632-41.
  39. Chen CJ, You SL, Pwu RF, Wang LY, Lin YP, Hsi GC, Hsi MS, Ho HC, Lee CT, Lin CG and et al. Community-based cervical cancer screening in seven townships in Taiwan. Journal of the Formosan Medical Association 1995;94 :S103-11

專書/專書篇章Book Chapter(s)
  1. 蒲若芳、楊雯雯、吳慧敏。追求分配正義建立臺灣NICE。載於黃煌雄、江東亮（主編）， 第三波健保改革之路（頁137-164）。台北市：遠見天下文化
  2. 湯澡薰、吳慧敏、蒲若芳。健康經濟與經濟評估。載於吳肖琪、鄭守夏(編輯)，衛生行政與管理。台北市：財團法人陳拱北醫學基金會
技術報告及其他Technical Reports and Others
  1. 陳冠如、洪瑜黛、楊雯雯、洪春旬、伍雪苹編輯（2023）。罕見疾病創新治療及藥物給付政策建言書（計畫總主持人：蔡輔仁；共同主持人：曾敏傑、蒲若芳、楊銘欽）。財團法人罕見疾病基金會。https://www.tfrd.org.tw/tfrd/assets/uploads/library_b1/66/tfrd_20231109142545.pdf
  2. Besley, S., Cole, A., Pwu, R., Hsieh, C., 2023. Real-World Evidence: Current Best Practice for Reimbursement Decision-making. OHE Contract Research Report, London: Office of Health Economics. Available at: https://www.ohe.org/publications/real-world-evidence-current-bestpractice/

國際參與Projects participating
    1. ISPOR Health Economic Publication Guidelines Good Reporting Practices Task Force (CHEERS) 2022.
    2. Development of new preference-based measure (PBM) for Asia, initiated by Center for Outcomes Research and Economic Evaluation for Health (C2H) and National Institute of Public Health (NIPH), Japan. Since 2019.
    3. RWE for HTA in Asia Working Group, initiated by Saw Swee Hock School of Public Health and HITAP. (since 2019)
    4. APAC Liver Disease Alliance.
    5. HTA for All initiative.
Back